CSF; G-CSF
Granulocyte colony-stimulating factor (G-CSF; filgrastim) mobilized HLA-matched sibling peripheral blood progenitor cell (PBPC) transplantation has improved outcomes for patients with advanced hematological malignancies by hastening hematopoietic engraftment and mitigating early infectious morbidity in comparison to unstimulated bone marrow (BM). [1] [2] [3] [4] [5] [6] [7] [8] Nevertheless, in only a minority of the randomized comparative trials did this translate into an overall survival advantage and some studies suggested the use of G-CSF mobilized PBPC was associated with a greater risk of either acute or chronic graft-versus-host disease (GVHD), or both. 6, [8] [9] [10] In two recent retrospective studies in patients with aplastic anemia or children with leukemia performed by the International Bone Marrow Transplant Registry, transplantation of G-CSF mobilized PBPC was associated with higher rates of GVHD. 11, 12 Therefore, strategies to limit GVHD following PBPC transplantation are necessary.
Our group has been interested in investigating the impact of alternative hematopoietic cytokine regimens for mobilizing PBPC from HLA identical donors. Granulocyte-macrophage colony stimulating factor (GM-CSF; sargramostim) given singly or combined with G-CSF has been effective in mobilizing sufficient autologous CD34 þ cells to support prompt hematopoietic recovery following high-dose therapy. [13] [14] [15] [16] However, it appears that as a single agent, G-CSF is more effective than GM-CSF in mobilizing CD34 þ cells. 14, 16, 17 Of note, several studies have demonstrated wide differences in the profile of monocytes, lymphocytes, and dendritic cells mobilized by the two agents. 14, 16, [18] [19] [20] Since these graft constituents are likely to exert an influence on the development of GVHD and graft-versus-malignancy effects, we sought to determine the clinical impact of donor PBPC mobilization regimens using GM-CSF alone or in combination with G-CSF. In this retrospective analysis of uniformly treated and supported patients, we found that the transplantation of PBPC from HLA identical sibling donors mobilized with GM-CSF alone was associated with similar engraftment kinetics compared to G-CSF alone, but lower rates of moderate to severe acute GVHD.
Methods

Patients and donors
Included in this retrospective analysis are a total of 166 HLA-identical sibling donor/recipient pairs enrolled between November 1995 and April 2003 on trials evaluating the impact of cytokine mobilization regimen. All patients were also enrolled on a companion protocol (95-0763) opened in November 1995 evaluating the effects of a cyclophosphamide and single dose total body irradiation (TBI) conditioning regimen, as previously described. 21 Eligible patients had advanced hematological malignancies suitable for transplantation and an HLA identical sibling donor willing and able to donate cytokine mobilized PBPC. Both patients and donors gave written informed consent on protocols approved by the Human Studies Committee at Washington University.
Cytokine mobilizing regimens
The mobilizing regimens were administered to donors as follows: GM-CSF alone at 10 mg/kg (GM10) subcutaneously once daily with leukapheresis (LP) commencing on day 5 (N ¼ 10); GM-CSF alone at 15 mg/kg (GM15) subcutaneously once daily with LP commencing on day 6 (N ¼ 21); both GM-CSF at 5 mg/kg and G-CSF 10 mg/kg (G/GM) subcutaneously once daily with LP commencing on day 5 (N ¼ 70); or G-CSF alone at 10 mg/kg (G) subcutaneously once daily with LP commencing on day 5 (N ¼ 65). LP was performed using peripheral venous access (17-gauge needle) whenever possible. In the vast majority of donors, large volume (18-20 l/session) LP was performed. All mobilized products were collected using the Cobe Spectra apheresis machine (Gambro BCT, Lakewood, CO, USA). The minimum CD34 þ cell dose for transplantation was set at 2.0 Â 10 6 CD34 þ cells/kg with a target dose set at 5.0 Â 10 6 CD34 þ cells/kg. LP continued until this target was reached or a maximum of three LP procedures were performed. Toxicities encountered by donors were graded according to the NCI common toxicity criteria (CTC) version 2.0.
Donors were first enrolled in the combination (G/GM) cohort and then on the GM10 cohort. The GM10 cohort was closed after two of 10 donors failed to mobilize a minimum level of 2 Â 10 6 CD34 þ cells/kg. Accrual to the G/GM cohort continued while a decision to reopen the GM-CSF alone cohort was being made. The GM-CSF cohort was later reopened at a higher daily dose (15 mg/kg) in an attempt to increase the number of CD34 þ cells mobilized. The first day of LP was also changed to day 6 for this cohort as it appeared that donors in the GM10 cohort had a slower rise in the peripheral blood CD34 þ cell count compared to the G or G/GM cohorts. An additional 21 donors were entered on the GM15 cohort. G-CSF was used as the standard mobilization regimen while the data from the alternative regimen groups (GM or G/GM) were being analyzed. Therefore, donors were not entered in a randomized manner.
Conditioning regimen, GVHD prophylaxis, and supportive care
All patients received the same conditioning regimen consisting of cyclophosphamide at 60 mg/kg (ideal weight or adjusted for obesity) intravenously daily for two doses on days À3 and À2 followed by single dose TBI delivered at a dose rate of 30 cGy/min for a total dose of 550 cGy on day À1. 21 All patients received fresh cytokine mobilized PBPC on day 0. No products were cryopreserved. All patients received the identical GVHD prophylaxis regimen consisting of cyclosporine at 3 mg/kg/day by continuous intravenous infusion beginning on day À2. Patients were switched to oral cyclosporine once able to tolerate. Target trough cyclosporine levels were 200-400 ng/ml. Cyclosporine tapering commenced on day þ 100 in the absence of GVHD. No methotrexate was given. All patients received subcutaneous G-CSF at 5 mg/kg/day beginning day þ 1 and continuing until the absolute neutrophil count (ANC) was over 1500/ ml for 3 days. All patients received prophylactic acyclovir but no routine bacterial or fungal prophylaxis was given. Patients with febrile neutropenia received broad-spectrum antibiotics according to Infectious Disease Society of America (IDSA) guidelines. 22 
Definitions
Neutrophil engraftment was defined as a rise in the ANC to 500/ml or greater for two consecutive days following a conditioning regimen induced nadir. Platelet engraftment was defined as the first day of platelet count greater than 20 000/ml without transfusion for seven consecutive days. Primary graft failure was defined as failure of neutrophil engraftment by day 28. Secondary graft failure was defined as primary engraftment followed by a drop in the neutrophil count to less than 500/ml for more than 3 consecutive days without any apparent cause such as drugs or opportunistic infection. Patients with acute leukemia in first complete remission, myelodysplastic syndrome with refractory anemia or refractory anemia with ring sideroblasts, and chronic myelogenous leukemia in chronic phase were considered to have low-risk disease. All other patients were placed in the high-risk disease category. Acute and chronic GVHD were graded according to the Seattle criteria. 23, 24 In most circumstances, attempts were made to obtain skin biopsies or biopsies of other relevant organs in order to confirm the diagnosis of acute or chronic GVHD, but the diagnosis could be made on clinical grounds only. Relapse was defined as reappearance of disease for patients in remission or the progression of disease for patients transplanted with active disease. Chimerism status was monitored in whole bone marrow preparations using short tandem repeat techniques typically on or around days 30, 100, 180, 365, and then yearly thereafter if still in remission. Full donor chimerism was defined as greater than or equal to 95% donor cells within the bone marrow.
Immunophenotyping
Immunophenotyping was performed on fresh specimens of PBPC or peripheral blood. Lineage negative (negative for CD3, CD14, CD11b, CD19) CD34 þ cells were measured by a modification of the technique of Roscoe et al. 25 Lymphocyte subsets were enumerated by mixing samples containing 1 Â 10 6 leukocytes with the following four cocktails of fluorescent conjugated antibodies (Beckman-Coulter, Fullerton, CA, USA): (1) CD3-FITC, CD-4-PE, CD8-ECD, and CD45-PE-Cy5; (2) CD3-FITC, CD56-PE, CD19-ECD, and CD45-PE-Cy5; (3) CD2-FITC and CD45-PE-Cy5, and (4) IgG 1 -FITC, IgG 1 -PE, IgG 1 -ECD, and CD45-PE-Cy5. After 30 min incubation at 41C, a red cell lysis procedure was performed using 0.15 M NH 4 Cl and samples were fixed with 1% paraformaldehyde. All flow cytometry analyses were performed on side scatter-CD45 gated lymphocytes using a Coulter Elite cytometer equipped with an argon laser (Beckman-Coulter).
Statistical considerations
Follow-up is through September 1, 2003 or on the last contact prior to that date. For analysis of clinical outcomes following transplantation (engraftment, GVHD, survival, relapse) data from both the GM10 and GM15 cohorts were pooled for comparison to the G/GM and G alone cohorts. Nonparametric Wilcoxon-Mann-Whitney tests were used to compare cell counts and Fisher's exact test was used to compare categorical variables among G-CSF, GM-CSF, and G þ GM-CSF cohorts. Kaplan-Meier and Cox proportional hazards models were used to compare time to acute GVHD, extensive chronic GVHD, relapse, disease progression, and death from any cause. Time to extensive chronic GVHD was examined among the subset of patients who were alive on day þ 100 after transplant.
Results
Patient and donor characteristics
There were no significant differences among the three patient groups (GM, G/GM, or G) with respect to age, sex, sex mismatching, or disease risk (low vs high) category ( Table 1) . The majority of patients in each cytokine group had high-risk disease. There were no significant differences between the three donor groups with respect to donor age, sex, or weight (Table 2) .
Most donors underwent large volume LP, processing up to 20 l of blood per LP procedure. The donors mobilized in the G or G/GM cohorts required fewer LP procedures compared to GM10 or GM15 in order to achieve the target CD34 þ cell dose (Table 2 ; P ¼ 0.001). Of the 31 donors mobilized on the GM alone arm, 12 (39%) required more than one LP procedure to achieve the minimum CD34 dose compared to only three of 65 (5%) with G alone and three of 70 (4%) with G/GM. The mean volume of blood processed per LP procedure in the GM-CSF cohort (18.7 l) was similar to that in the G-CSF cohort (19.2 l, P ¼ 0.18) but less than the G/GM-CSF cohort (19.7 l, P ¼ 0.002). However, the GM-CSF cohort had the highest amount of total blood processed overall since they required more LP procedures to achieve the minimum CD34 þ cell dose.
Allograft analysis
The minimum CD34 þ cell dose (2.0 Â 10 6 /kg) was not achieved in 2/10 donors in the GM10 cohort and 1/21 in the GM15 cohort compared to 2/65 in the G and 0/70 in the G/GM cohorts (Po0.01 for GM10 vs G or G/GM). The target CD34 þ cell dose (X5.0 Â 10 6 /kg) was achieved in 26% of donors in the GM cohorts, collectively, compared to 74 and 72% in the G and G/GM cohorts, respectively (P ¼ 0.01). Grafts mobilized following GM10 and GM15 contained significantly fewer CD34 þ cells/kg recipient weight (3.671.8 and 4.072.3, respectively) compared to G or G/GM (8.675.2 and 10.378.4, respectively; Po0.001 for all comparisons) ( Table 2 ). The G/GM cohort mobilized the greatest number of CD34 þ cells, but the Table 1 Baseline characteristics of patients 
difference was not significant compared to G-CSF alone. Grafts mobilized following GM alone contained significantly fewer CD3 cells compared to G alone, but there were no significant differences in other cell subsets. (Table 2 ). This takes into account the fact that donor allografts collected following GM alone required more total blood volume processing via leukapheresis. On a per leukapheresis basis, however, fewer CD3, CD4, CD8, CD19, and CD16/56 were collected following GM alone compared to G alone. Allografts mobilized following G/GM alone contained significantly fewer CD3, CD4, CD8, and CD16/56 þ cells compared to G alone. There were no significant differences in these cell subsets comparing G/GM to GM alone.
Toxicity of cytokine mobilization regimens
Two donors in the GM15 cohort required hospitalization for CTC grade 3 hypotension and fever, resulting in closure of this cohort. Two donors in each of the cytokine cohorts required central venous catheters in order to complete leukapheresis. There were no other significant differences in the toxicities encountered in any of the cohorts.
Hematopoietic engraftment and chimerism
A total of five patients in this study received allografts containing less than 2.0 Â 10 6 CD34 þ cells/kg. None of these patients received any additional boost such as supplemental BM. Despite the lower CD34 þ cell doses transplanted in the GM10 or GM15 recipients, the time to neutrophil recovery did not differ significantly among the groups (GM10/15: 10.173.2 days; G þ GM: 10.372.1 days; G: 9.972.7 days (mean7s.d.); P ¼ NS). There was no significant difference in time to platelet engraftment among the three cohorts (GM10/15: 14.27 10.6 days; G þ GM: 14.5710.7 days; G: 13.9710.7 days (mean7s.d.); P ¼ NS). Following transplantation, there was no difference in the incidence of full or mixed BM chimerism between the three cohorts (data not shown). In general, full donor chimerism (X95% donor cells) was observed by day 30, as previously described. 21 There were no early or late graft failures observed in any of the cohorts.
Graft-versus-host disease
The cumulative incidence of grade II-IV acute GVHD in the GM10/15 alone cohorts (13%; 95% CI: 4%, 30%) was significantly lower than that observed in the G alone (49%; 95% CI: 36%, 62%; Po0.001) or the G/GM group (69%; 95% CI: 56, 79; Po0.001) (Figure 1 ). The incidence of grade III to IV acute GVHD was higher in the G alone (12%; 95% CI: 6, 23) alone and G/GM (10%: 95% CI: 4, 20) groups compared to GM-CSF alone (0%), but did not reach statistical significance due to the low incidence in all cohorts (Figure 2 ). Acute GVHD involvement of all potential organs (skin, liver, GI tract) was lower in the GM10/15 cohorts compared to G alone or the G/GM group. In a multivariate Cox proportional hazards analysis including patient and donor age, sex mismatching, mobilizing regimen, disease risk, and the following cell doses: CD34 þ , CD3 þ , CD4 þ , CD8 þ , CD19 þ , and CD16/ 56 þ , only the use of GM-CSF for donor mobilization was associated with a reduced risk of grade II-IV acute GVHD (Table 3 ). The hazard ratio of 0.21 (95% CI 0.073, 0.58) indicates that these patients were no more than about 60% as likely to develop grade II-IV acute GVHD as were patients receiving grafts mobilized with G-CSF alone. Interestingly, in a Cox proportional hazards model the risk of grade II-IV acute GVHD was significantly higher in the G/GM group compared to the G-CSF alone group (P ¼ 0.011, hazard ratio 1.79 95% CI: 1.14, 2.81). The hazard ratio of 1.79 (95% CI 1.14, 2.8) indicates that these patients had an additional risk of developing grade II-IV acute GVHD of at least 14% as were patients receiving grafts mobilized by G-CSF alone. We could not identify any association between the CD34 þ cell dose and the risk of either acute or chronic GVHD when we analyzed CD34 þ cell dose as a continuum, in quartiles, or above or below any defined cutoff points in the multivariate model. When CD34 þ cell dose was included as the sole covariate in a model of time to acute GVHD, it was associated with an increased risk of acute GVHD. In fact, the hazard of acute GVHD is elevated by 1-6% for each increase of 1 Â 10 6 in CD34 þ count. This is not an informative model, though, because growth factor use was also related to the probability of acute GVHD and the range of CD34 þ doses was quite different in each of the three growth factor classes. The most useful model was one that included growth factor and CD34 þ doses as covariates. This model estimated the effect of growth factor while taking into account (or adjusting for) the effect of CD34 þ cell dose. The result indicated that the effect of growth factor overshadows the effect of CD34 þ cell dose, so that the latter had a nonsignificant P-value. That is, CD34 þ count did not provide any additional information about the risk of acute GVHD over and above that provided by growth factor. The same was true in the analysis of other graft constituents.
The cumulative incidence of extensive chronic GVHD (GM10/15: 87%, (95% CI: 60, 98); G/GM: 93%, (95% CI: 81, 99); G: 88%, (95% CI: 75, 96) was high in all cohorts and did not differ significantly among the three groups.
Relapse and survival
The median follow-up of the surviving patients in all cohorts is 45 months (range 4-72). Owing to the time lag between the closure of the GM10 cohort and opening of the GM15 cohort, the median follow-up was shorter in the GM cohort (20.5 months) compared to the G alone (49 months) and G/GM (46.5 months) cohorts. The actuarial risk of relapse at 2 years following transplantation was not significantly different among any of the mobilization groups (G alone: 34%, G/GM: 46%, GM alone: 34%) (Figure 3) . The 2-year estimate of overall survival (G alone: 52%, G/GM: 42%, GM alone: 47%) did not differ significantly among any of the mobilization groups (Figure 4 ). There were no significant differences among the groups with respect to relapse risk or overall survival based on disease risk category (data not shown). Relapse was the most common cause of death among all of the cohorts, accounting for more than half of all the deaths observed (Table 4) . Deaths attributable to GVHD were less common in the GM alone group (two of 16 (12.5%)), compared to the G-CSF alone (nine of 34 (26%)) or the G/GM (14 of 46 (30%)) groups, although the differences were not statistically significant (P ¼ 0.39).
Discussion
We studied the effects of various cytokine mobilization strategies in a group of uniformly treated patients receiving HLA identical sibling PBPC transplantation for advanced Table 4 Causes of death by cytokine group Relapse  16  25  9  GVHD  1  4  0  Infection with GVHD  8  10  2  Infection, no GVHD  5  2  3  Regimen related toxicity  4  5  2 GVHD ¼ graft-versus-host disease.
hematological malignancies. To our knowledge, this is the largest study to date evaluating alternative cytokine mobilization regimens in allogeneic blood cell donors.
The results demonstrate that GM-CSF mobilized allografts contain significantly lower total doses of CD34 þ and CD3 þ cells compared to G-CSF mobilized allografts without compromising engraftment kinetics or graftversus-malignancy effects. Moreover, compared to G-CSF, allografts collected following mobilization with GM-CSF alone may be associated with a diminished risk of moderate to severe acute GVHD. Weaknesses of this analysis include the fact that the study was not prospective, the investigators grading GVHD were not blinded to the cytokine group, and the patient populations were relatively heterogeneous. Nevertheless, the observations are provocative. GM-CSF has been used previously to mobilize autologous PBPC either in combination with chemotherapy or as a single agent. [13] [14] [15] [16] It is effective for these purposes, although does not appear to stimulate the mobilization of as many CD34 þ cells as G-CSF. Our results, as well as those reported previously from other groups, demonstrate that GM-CSF used as a single agent is less effective than G-CSF for mobilization in normal donors. [16] [17] [18] Allografts mobilized by GM-CSF alone contained significantly fewer CD34 þ cells in comparison with G or G/GM and the donors required more LP procedures to obtain both the minimum and target CD34 þ cell doses. Further, several donors failed to reach a target of 5.0 Â 10 6 CD34 þ cells/kg and three of 31 (9.7%) mobilized less than 2.0 Â 10 6 CD34 þ cells/kg. Nevertheless, all recipients of GM-CSF mobilized allografts engrafted neutrophils and platelets promptly and there were no late graft failures observed. Such observations challenge the notion that CD34 þ cell doses greater than 4.0-5.0 Â 10 6 /kg are necessary to consistently promote sustained hematopoietic engraftment following HLA-identical sibling PBPC transplantation. These results should highlight the need for further investigation into the range of characteristics that constitute an 'optimal' PBPC allograft. [26] [27] [28] There appeared to be a modest dose-response effect with GM-CSF since donors mobilized greater total numbers of CD34 þ cells following an increase in the dose of GM-CSF to 15 mg/kg/day. However, we noted that the kinetics of CD34 þ mobilization in the GM10 group were more gradual in comparison to G-CSF, with peak CD34 þ cell levels achieved on days 6-7 rather than the typical days 4-5 peak observed following G-CSF. This was in line with previous observations. 14,16,17 Accordingly, we decided to withhold the first LP procedure until day 6 in the GM15 cohort we studied next. This change in schedule may have accounted for the slightly greater number of CD34 þ cells collected. Unfortunately, higher and more protracted dosing of GM-CSF was associated with greater toxicity and two donors in this group developed grade 3 fevers and hypotension. Therefore, the 15 mg/kg/day dosing schedule of GM-CSF appears too toxic for use in healthy volunteers and cannot be endorsed for these purposes.
The content of T cells, B cells, and NK cells within the allografts collected following GM-CSF alone or G-CSF combined with GM-CSF differed markedly compared to G-CSF mobilized allografts. Both the GM10/15 and the G/ GM groups mobilized allografts containing significantly lower doses of CD3 þ cells compared to G-CSF alone. Lymphocyte subset analysis revealed that G/GM mobilized allografts also contained significantly less CD4 þ , CD8 þ , and CD16/56 þ cells compared to G-CSF mobilized allografts. Quantitative differences in these cellular constituents may have impacted the risk of acute GVHD. However, on univariate analysis CD3 þ cell dose did not appear to influence the risk of either grade II-IV acute GVHD or chronic GVHD. Analysis of other lymphocyte subsets also failed to reveal that these differences exerted any significant influence on the risk of GVHD. Furthermore, the recipients of grafts mobilized by G/GM had the highest risk of acute GVHD despite receiving significantly lower CD3 þ doses compared to the G-CSF alone group.
These results suggest that qualitative differences in either the T cells or other accessory cells mobilized by the various cytokine regimens not readily identifiable by this analysis may have accounted for the reduced risk of acute GVHD observed in the GM-CSF group. Increased mobilization of CD4 þ CD25 þ T-regulatory (T reg ) cells has been observed following GM-CSF. [29] [30] [31] T reg have recently been associated with a reduction in the risk of GVHD in murine models. 32, 33 In mice, GM-CSF is associated with mobilization of more DC2 (plasmacytoid) type dendritic cells, which may downmodulate immune responses by shifting the T helper phenotype to a Th2 profile. 29, 34, 35 This was recently demonstrated in an autoimmune thyroiditis model. 29 Single-agent cyclosporine was used for GVHD prophylaxis in this study. Therefore, it is unknown whether these results can be extrapolated to recipients of cytokine mobilized PBPC administered multiagent pharmacologic prophylaxis with cyclosporine plus methotrexate (MTX), cyclosporine plus mycophenolate mofetil, or tacrolimus containing combinations. Nevertheless, the incidence of grades 2-4 acute GVHD observed in the G-CSF group in this trial (49%) is clearly in line with rates (21-64%) reported in the PBPC arms of several randomized trials. [1] [2] [3] [4] [5] [6] [7] The lack of any grade 3-4 acute GVHD in the GM-CSF group is noteworthy given the large proportion of patients transplanted for high-risk disease.
Despite the lower risk of moderate to severe acute GVHD with GM-CSF-based mobilization, there did not appear to be any influence on the incidence of chronic GVHD. Since prior onset of acute GVHD heavily influences the risk of chronic GVHD, we cannot readily explain this observation. However, the pathogenesis of chronic GVHD remains poorly understood. 36, 37 Other factors impacting the development of chronic GVHD such as the degree of thymic involution, deletion of alloreactive T cells, emergence of effector memory T cells, and the development of T reg may be heavily influenced by characteristics intrinsic to the host. While some studies have suggested that high doses of CD34 þ cells are associated with a greater likelihood of chronic GVHD, our data suggest that other factors may be more important since the risk of chronic GVHD was high within GM-CSF group despite the fact that they received a relatively modest median CD34 þ cell dose (3.1 Â 10 6 /kg). 10, 38, 39 Despite the fact that the cohort of donors receiving combination G/GM-CSF mobilized the greatest numbers of CD34 þ cells without significant additive toxicity, this did not translate into any clear clinical advantages to the recipients as the rate of hematopoietic engraftment, incidence of chronic GVHD, risk of relapse, and overall likelihood of survival did not differ significantly from the G-CSF alone group. In fact, the risk of acute GVHD was greatest in this combination group. We therefore have discontinued the combination regimen for donor PBPC mobilization. Perhaps this regimen may be considered in settings where very high CD34 þ cell doses could be useful, such as following T-cell-depleted haploidentical transplantation or prior to tandem autologous PBPC transplantation.
Other smaller studies evaluating the effects of GM-CSF for donor mobilization have been reported. 16, 17, 40, 41 In one, GM-CSF alone administered at a dose of 10 mg/kg/day was also not very effective at mobilizing CD34 þ cells (median CD34 þ cell dose: 3.3 Â 10 6 /kg). 17 Eight patients received allografts mobilized following GM-CSF alone on that trial and the rate of grades II-IV acute GVHD was 43%. However, given the small number of heterogeneously treated patients on that trial, it is difficult to reach any definitive conclusions. Other trials combining GM-CSF with G-CSF have suggested a greater frequency of phenotypically primitive CD34 þ cells mobilized compared to G-CSF alone, but our results suggest this may not translate into any significant clinical benefit. 40, 41 It is possible that our findings are not due to the effects of GM-CSF on the allograft per se, but rather that allografts mobilized following GM-CSF alone contain significantly fewer CD34 þ cells, resulting in a lower risk of acute GVHD, as previously suggested by another group. 42 However, the observation that higher CD34 þ cell doses are associated with a greater risk of acute GVHD has not been supported by other studies and a mechanistic basis for the observation remains elusive. 39, 43 On multivariate analysis, we were unable to find any association between CD34 þ cell dose and the risk of acute GVHD. We therefore consider our observations as hypothesis generating rather than definitive.
In summary, patients receiving HLA identical sibling allografts mobilized following GM-CSF alone have similar rates of hematopoietic engraftment but appear to be at a lower risk of grade 2-4 acute GVHD compared to recipients of allografts mobilized following G-CSF or G-CSF and GM-CSF in combination. However, GM-CSF does not reliably mobilize sufficient quantities of CD34 þ cells at the 10 mg/kg/day dose and at higher daily doses is too toxic. PBPC allografts containing lower CD34 þ cell doses (in the range of 2-4 Â 10 6 /kg) may be sufficient to ensure trilineage engraftment while limiting the risk of GVHD in HLA-matched siblings. Future studies evaluating this hypothesis may be warranted.
